Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, and promises to continue to expand. Experimental study of hallucinogen-assisted treatment, and any future clinical use, requires the development of psychotherapeutic models that are appropriate to the disorder being treated and effectively integrated with the pharmacologic component of the treatment. To provide a framework for thinking about possible treatment models, we provide an overview of the history of psychedelic-assisted treatment, review what is known about the therapeutic mechanisms of these treatments, and consider the various purposes of psychotherapy in the context of both research and clinical use of psychedelic-assisted treatment. We then provide a description of a therapy model we have developed and are currently using in a trial of psilocybin-assisted treatment for alcoholism. Finally, we discuss advantages and disadvantages of a range of alternative models, emphasizing the need for research to determine the most effective treatment models for any indications for which efficacy becomes established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motivational Interviewing: Preparing People for Change, 2nd ed.
Miller, W., & Rollnick, S. (2003) · Journal For Healthcare Quality · doi:10.1097/01445442-200305000-00013 · Cited by 2,634
(1997) · Journal of Studies on Alcohol · doi:10.15288/jsa.1997.58.7 · Cited by 1,905
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 2×
“…coupling of activity within functional networks such as the default mode network, and increasing functional connectivity between networks (Carhart-Harris et al., 2012; Carhart-Harris et al., 2013; Carhart-Harris et al., 2014; Roseman, Leech, Feilding, Nutt, & Carhart-Harris, 2014;…”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 6×
“The recently published pilot studies of psilocybin for alcohol and nicotine dependence have reported decreases in craving and increases in self-efficacy following psilocybin administration (Bogenschutz et al., 2015; M. W. Johnson et al., 2014).”
BackgroundMethodInfluentialSelf-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“The recently published pilot studies of psilocybin for alcohol and nicotine dependence have reported decreases in craving and increases in self-efficacy following psilocybin administration (Bogenschutz et al., 2015; M. W. Johnson et al., 2014).”
BackgroundBowen, S., Witkiewitz, K., Clifasefi, S. L., Grow, J., Chawla, N., Hsu, S. H., Carroll, H. A., Harrop, E., Collins, S. E., Lustyk, M. K., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4546 · Cited by 701 · cited 1×
“…Research Group, 1997, 1998a; Tonigan & Bogenschutz, 2008), motivational interviewing/ MET (Lundhal & Burke, 2009), family/couples therapies (Powers, Vedel, & Emmelkamp, 2008; Roozen, de Waart, & van der Kroft, 2010), and mindfulnessbased approaches (S. Bowen et al., 2014; Witkiewitz et al., 2014).”
Magill, M., & Ray, L. A. (2009) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2009.70.516 · Cited by 694 · cited 1×
“…for addictions appear to be adaptable for use in the context of hallucinogen-assisted treatment, including cognitive behavioral approaches (Magill & Ray, 2009), 12-step facilitation (Project MATCH Research Group, 1997, 1998a; Tonigan & Bogenschutz, 2008), motivational interviewing/ MET…”
MethodLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“A recent meta-analysis (Krebs & Johansen, 2012) revealed consistent and clinically meaningful effects of LSD over control treatment in the six randomized trials of LSD for alcohol dependence that reported drinking outcomes, including a total of 536 participants (W. T. Bowen, Soskin, & Chotlos,…”
BackgroundLundahl, B., & Burke, B. L. (2009) · Journal of Clinical Psychology · doi:10.1002/jclp.20638 · Cited by 573 · cited 14×
“The alcohol therapy component consists of MET followed by Cognitive Behavioral Therapy sessions including implementation of specific strategies for change during the later sessions.”
InfluentialSINHA, R., & LI, C. ‐. R. (2007) · Drug and Alcohol Review · doi:10.1080/09595230601036960 · Cited by 497 · cited 1×
“Anxiety and stress are important triggers for relapse to substance use (Sinha & Li, 2007), so it is possible that 5HT2A receptor downregulation by classic hallucinogens could alter and diminish stress-induced relapse.”
BackgroundVaidya, V. A., Marek, G. J., Aghajanian, G. K., & Duman, R. S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02785.1997 · Cited by 479
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Prediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339 · cited 2×
“A recent publication reported that “ego disintegration” during psilocybin administration was associated with decreased functional connectivity of the medial temporal lobe (anterior parahippocampal cortex in particular) and decreased functional integrity of the salience network (Lebedev et al., 2015).”
BackgroundKraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 1×
“The primary molecular target of all classic hallucinogens is thought to be the serotonin 2A (5HT2A) receptor (Halberstadt, 2015; Nichols, 2004), which is rapidly down-regulated following hallucinogen administration.”
BackgroundBehavioral couples therapy (BCT) for alcohol and drug use disorders: A meta-analysis
Powers, M. B., Vedel, E., & Emmelkamp, P. M. G. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.02.002 · Cited by 300
Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256 · cited 2×
“Psilocybin appears to cause a loosening of organization in brain activity, decreasing coupling of activity within functional networks such as the default mode network, and increasing functional connectivity between networks (Carhart-Harris et al., 2012; Carhart-Harris et al., 2013; Carhart-Harris et al., 2014; Roseman…”
BackgroundKetamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 1×
“…in the 1990s provided evidence for the efficacy of the NMDA (N-methyl-D-aspartate) receptor antagonist psychedelic ketamine in the treatment of alcohol and heroin dependence (E. Krupitsky et al., 1992; E. Krupitsky et al., 2002; E. M. Krupitsky et al., 2007; E. M. Krupitsky & Grinenko, 1997).”
BackgroundKetamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Frokjaer, V. G., Mortensen, E. L., Nielsen, F. Å., Haugbol, S., Pinborg, L. H., Adams, K. H., Svarer, C., Hasselbalch, S. G., Holm, S., Paulson, O. B., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.009 · Cited by 242 · cited 3×
“Increased 5HT2A receptor binding has been reported in people with psychiatric conditions including depression (Shelton, Sanders-Bush, Manier, & Lewis, 2009), neuroticism (Frokjaer et al., 2008), borderline personality disorder (Soloff et al.”
InfluentialAssessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227 · cited 2×
“There is increased recognition that the use of psychedelics in the context of organized religious activity is associated with few if any deleterious effects, and is associated with decreased rates of substance use disorder (Albaugh & Anderson, 1974; Barbosa, Mizumoto, Bogenschutz, & Strassman, 2012; Doering-Silveira e…”
BackgroundRapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signaling
Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905884106 · Cited by 226 · cited 2×
“remodeling of pyramidal cell dendrites (Jones et al., 2009).”
BackgroundThe experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220 · cited 1×
“Clinical work with psychedelics has generally assumed that the patient’s conscious experience during the drug’s acute effects is essential for long-term clinical benefit (Grof, 2008; Hoffer, 1967; Masters & Houston, 2000; Pahnke et al., 1970; Sherwood et al., 1962).”
BackgroundRoozen, H. G., De Waart, R., & Van Der Kroft, P. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03016.x · Cited by 178
Psychotherapy with lysergic acid diethylamide
EISNER, B. G., & COHEN, S. (1958) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-195812000-00006 · Cited by 138
Witkiewitz, K., Warner, K., Sully, B., Barricks, A., Stauffer, C., Thompson, B. L., & Luoma, J. B. (2014) · Substance Use & Misuse · doi:10.3109/10826084.2013.856922 · Cited by 137 · cited 2×
“Many empirically validated forms of psychosocial treatment for addictions appear to be adaptable for use in the context of hallucinogen-assisted treatment, including cognitive behavioral approaches (Magill & Ray, 2009), 12-step facilitation (Project MATCH Research Group, 1997, 1998a; Tonigan & Bogenschutz, 2008), moti…”
MethodPeyote in the Treatment of Alcoholism Among American Indians
ALBAUGH, B. J., & ANDERSON, P. O. (1974) · American Journal of Psychiatry · doi:10.1176/ajp.131.11.1247 · Cited by 128 · cited 1×
“…of organized religious activity is associated with few if any deleterious effects, and is associated with decreased rates of substance use disorder (Albaugh & Anderson, 1974; Barbosa, Mizumoto, Bogenschutz, & Strassman, 2012; Doering-Silveira et al., 2005; Fabregas et al., 2010; Garrity, 2000;…”
BackgroundReport on psychoactive drug use among adolescents using ayahuasca within a religious context.
Doering-Silveira, E., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Da Silveira, D. X. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399794 · Cited by 122
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
Self-citation(1969) · doi:10.1176/ajp.125.10.1352 · Cited by 106
Conceptualizations of relapse: a summary of psychological and psychobiological models
CONNORS, G. J., MAISTO, S. A., & DONOVAN, D. M. (1996) · Addiction · doi:10.1111/j.1360-0443.1996.tb02323.x · Cited by 104
Cited by
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Self-citationSloshower, J., Guss, J., Krause, R., Wallace, R. M., Williams, M. T., Reed, S., & Skinta, M. D. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.002 · Cited by 171
Psychedelic harm reduction and integration: A transtheoretical model for clinical practice
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645246 · Cited by 147
“PHRI is influenced by psychedelic-assisted psychotherapy practices (Mithoefer, 2013; Bogenschutz and Forcehimes, 2017), IHRP (Tatarsky, 2007), relational-psychodynamic theory, and mindfulness-based interventions (Segal et al.”
BackgroundEthical and legal issues in psychedelic harm reduction and integration therapy
Pilecki, B., Luoma, J. B., Bathje, G. J., Rhea, J., & Narloch, V. F. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00489-1 · Cited by 141
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90
Metadata
- Authors
- Bogenschutz, M. P., & Forcehimes, A. A.
- Venue
- Journal of Humanistic Psychology
- Publisher
- SAGE Publications
- Published
- 2016-10-16
- Volume
- 57
- Issue
- 4
- Pages
- 389-414
- ISSN
- 0022-1678 (ISSN-L)
- 1552-650X
- OpenAlex
- W2537388000
- Cited by
- 97
- References
- 37
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.